Forte Medical case study within Imperial College Innovation paper

Commissioned by Lord Sainsbury and authored by Professor James Moore and Yunus Kutlu, Imperial College has published a report on innovation adoption in the UK and wh

at prevents successful adoption of impactful innovation. Forte Medical features as the only case study and outlines issues with silo systems, a disconnect between procurement and fincance all topped off with vested interests from labs and leadership.

The Peezy Midstream case study outlines how adoption of preventative devices and practice are resisted, leading to missed opportunities for improved patient health, prompt diagnoses, prevention and huge cost savings across the patient pathway.

Read all about it here. – see Page 29 and Appendix 2

Imperial Business School: a MedTech to Market Journey

Giovanna’s annual talk to the Imperial Business School took place last week; here we share the presentation Deck. Had she known in 2002 what she knows now, it would have taken a third of the time to create three specimen collection products and a springboard to global reach. She and Dr Vincent Forte are beyond proud of what they have achieved. 202210_ForteMedical_HealthTech_Commercialisation_Journey

Informa: Giovanna Forte one of 30 Rising Leaders in Life Sciences

We are delighted to share the Informa list of 30 Rising Leaders in Life Sciences, which features Forte Medical’s very own CEO Giovanna Forte. Click here for the full story.

US Partnership Deal With Owen Mumford Announced

The partnership between Forte Medical and Owen Mumford USA was launched today at the OCTANe Medical Innovation Technology Forum (MTIF) at Newport Beach, CA 28-29 October 2019. 

Introducing Peezy Midstream to the USA has long been an ambition of Forte Medical. Our disruptive and innovative MedTech called for a partner with experience, knowledge and a savvy mindset. We found that partner in Atlanta-based Owen Mumford USA whose reach covers the USA and Canada and is managed by Travis Shaw.

Owen Mumford has been at the forefront of medical device innovation for over 65 years, creating solutions that improve the delivery of healthcare and home health treatments for people around the world. Their products span devices that make blood testing more comfortable to solutions that make it easier to administer life-saving medication.

Owen Mumford’s experience in medical devices began in the 1950s when founders Ivan Owen and John Mumford established the company. The company have direct sales offices and a network of distribution partners serving customers in over 60 countries, and employ over 800 people across the Americas, Europe and Asia.  

“Owen Mumford USA is delighted to partner Forte Medical in North America and Canada,” says Travis Shaw. “Our team looks forward to expanding our mutual synergies. Research indicates that Peezy Midstream can add significant clinical and cost value to healthcare providers, a true win-win for all parties.”
 
Thanks to the Greater Irvine Chamber of Commerce for making this possible.

urine infection medication

Comment On Incentivising Companies To Develop New Antibiotics

It is very interesting to read that pharma companies are to be incentivised to develop new antibiotics to combat antimicrobial resistance (AMR). A significant yet consistently overlooked contribution to the problem of AMR is unreliable urine collection and analysis, which leads to the staggeringly high rates of broad-spectrum antibiotic prescribing that is fuelling the AMR crisis.

NHS Improvement data confirms that 50% of the global rise in AMR has a urinary source and that Urinary Tract Infection (UTI) is being routinely treated with increasingly pointless broad spectrum antibiotics.

All NHS and Public Health England guidelines specify that midstream urine is required for accurate analysis. There is no guarantee that this occurs as there is no protocol for urine collection. We know from a 2016 FOI request to all NHS Trusts that urine specimen contamination rates reach as high as 70%, with an average of 23%. This means 15m people a year are not being accurately diagnosed and are generally prescribed a broad spectrum antibiotic that will not treat their condition.

Some years ago, in response to failed UTI treatment amongst his patients, a diligent NHS GP identified this problem and invented a low-cost, British made medical device that collects midstream urine specimens. It has taken almost 15 years for us to persuade the NHS that his device is worth using; clinical trial results confirm its efficacy and substantial cost savings due to reduced retesting and false-positive urine specimens. Our world-first device delivers win-win for diagnostics, clinicians, patients, AMR and NHS finances all for 87p. Can the pharma companies compete with this?

Before the Government “incentivises” the already well-off pharma industry to develop new medicines, it would do well to get the basics right and look to NHS generated innovation to help it succeed. As it happens, our British SME is looking for investment; perhaps the Government would instead like to incentivise our work in delivering a tangible, ready-made solution for this global problem?

Urine specimen testing

Urine Is Liquid Gold When It Comes To Testing

Today’s Hippocratic Post features an overview on the importance of urine and the evidence supporting why our technology plays such a vital role in enabling right-first-time diagnosis and treatment.

 

Forte Medical Review

A Year In Review – 2018

  • New evidence showing a 70% reduction in false positive dipped specimens
  • Extended uptake by the NHS
  • Investment including a JV to create a Smart Peezy
  • Sheena Byrom joining our Advisory Panel
  • Being recognised in the Sunday Times 2018 Maserati 100 list that celebrate British entrepreneurship

These have been a few of our highlights for 2018 – to read more, please click here

Sheena Byrom Joins Our Advisory Panel

We are delighted to announce the appointment of consultant midwife and lifelong campaigner for positive childbirth, Sheena Byrom OBE to our Advisory Panel.

Sheena Byrom is a practising midwife of 40 years, having worked in the NHS for most of that time. One of the UK’s first consultant midwives, and as head of midwifery, she successfully helped to lead the development of three birth centres in East Lancashire. An international speaker, Sheena provides consultancy services to both NHS Trusts and to organisations globally; helping them to support normal, physiological childbirth. She is involved in several midwifery related charities, and is one of the project leads of the Midwifery Unit Network, which assists and promotes midwifery led units (birth centres) both online, and face-to-face. Sheena and her midwife daughter Anna Byrom are the proud new owners of The Practising Midwife, and an exciting online platform All4Materity.com – the go to place for maternity workers to learn, share and care.

Sheena’s midwifery memoirs, Catching Babies, is a Sunday Times bestseller, and her seminal book, The Roar Behind the Silence: why kindness, compassion and respect matter in maternity care jointly edited with Soo Downe, is being used as a resource to improve maternity care throughout the world.  Sheena and Soo are currently editing a second book, ‘Squaring the Circle: researching normal childbirth in a technological world’, will be published in 2019.

Sheena was awarded an OBE in 2011 for services to midwifery, and was made an Honorary Fellow of the Royal College of Midwives in 2015. In 2016 and 2018, Sheena received Honorary Doctorates from Bournemouth University and the University of Central Lancashire, and in 2017 she was made a Visiting Fellow at Bournemouth University. Her personal and midwifery related website is sheenabyrom.com.

Sheena is committed to the humanisation of childbirth, to maximising normal physiological birth processes, and for all women to experience a positive birth. The global onslaught of medical technology as a means to improve safety continues to influence childbearing women’s physiology and autonomy, and her work to reverse the trend is ongoing.

Commenting on her appointment, Giovanna Forte said: “With over 5 million urine samples provided every year by pregnant women and up to 1 in 4 of those being contaminated, it is incredibly important to us to have someone of Sheena’s expertise, knowledge and practical experience in the antenatal sector to help us.  We very much look forward to working with her to positively change attitudes towards urine specimen collection and further help improve right-first-time diagnosis and appropriate treatment for pregnant women as well as the well-being of mother and baby.”

 

Forte Medical UCI conference

Attending the Greater Irvine Chamber’s 2018 Life Sciences

Giovanna Forte, CEO was delighted to be one of 10 British executives to make their way to UC Irvine (UCI) for the Greater Irvine Chamber’s 2018 Life Science Showcase event.

In collaboration with UCI Applied Innovation, the Greater Irvine Chamber hosted UK owned life science companies to position Southern California and UCI as a strong global brand for innovation and entrepreneurship. Applied Innovation worked closely with the chamber to promote industry cluster growth in the region.

Click here to read more about the event

Peezy Usability Study Forte Medical

Peezy Midstream Case Study at NHS NIHR Conference 2018

Back in March of this year, the NHS National Institute for Health Research contacted Forte Medical, asking for a case study demonstrating how their research has assisted the launch of Peezy Midstream.

A few months earlier the NIHR in conjunction with the West Midlands AHSN conducted a valuable Usability Study on our diagnostic device. Results were excellent and have assisted us with adoption training and reassurance to HCPs and patients alike that using Peezy Midstream is far, far easier than trying to deliver this elusive urine specimen any other way …

The case study presented by Giovanna Forte on 10th October 2018 was very well received and has already led to enquiries from Primary Care clinicians who can see the benefit of right-first-time diagnoses for UTI and other common conditions that can take up so much GP time when left untreated.

2018 NIHR Peezy Presentation

NIHR_PeezyMidstream-Case-Study